Curis (CRIS) Projected to Post Earnings on Tuesday

Curis (NASDAQ:CRIS) will likely be posting its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Curis to post earnings of ($0.3267) per share and revenue of $1.6870 million for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $1.14 million during the quarter, compared to analyst estimates of $3.25 million. On average, analysts expect Curis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Curis Price Performance

Curis stock opened at $0.59 on Monday. The business’s 50-day simple moving average is $0.76 and its 200 day simple moving average is $1.02. The stock has a market cap of $23.67 million, a price-to-earnings ratio of -0.50 and a beta of 3.08. Curis has a 12-month low of $0.49 and a 12-month high of $3.13.

Institutional Investors Weigh In On Curis

Several large investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in shares of Curis in the fourth quarter worth about $26,000. Squarepoint Ops LLC increased its holdings in shares of Curis by 46.2% in the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 27,343 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Curis by 37.3% in the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 65,404 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of Curis by 2,883,237.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 230,659 shares in the last quarter. 29.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Curis to a “hold” rating in a report on Saturday, March 28th. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Curis in a research note on Friday, March 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Curis currently has a consensus rating of “Hold” and a consensus price target of $17.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.